Objective Personalized medicine aspires to provide optimal therapy in real-time during patient treatment, however current methodology falls short to deliver this in a robust manner. With this in mind, we invented a method for the screening of thousands of drug responses in small samples of an individual’s peripheral blood by automated microscopy and single-cell image analysis. We termed this method pharmacoscopy. In the course of carrying out the i-FIVE ERC grant project plan, we began screening for novel anti-viral or immune modulating drugs. In the quest to increase the physiological relevance of our screening settings, we investigated the possibility of using peripheral blood cells or bone marrow from individuals. We have thus far been able to show that the approach allows for the screening of anti-inflammatory properties of compounds, and to score for distinct sub-population specific cell cytotoxicity profiles of clinical anti-neoplastic agents through the tracking of fluorescent antibodies and probes. Moreover, we have been able to show that the approach empowers the therapeutic decision-making capability of hema-oncologists in a concrete clinical setting using primary myelofibrosis and lymphoma as test diseases. With funding from this grant, we intend to obtain further clinical data through retrospective trials, and incorporate the results into an information package attractive enough to draw the attention of potential investors. We have secured the intellectual property rights and have assembled the know-how required to enable commercialization efforts. With the unique image-based single cell analysis of human liquid tissues, we believe that chemos has the potential to develop into a service that enables and advances personalized medicine and drug discovery for a broad spectrum of hematological disorders. Fields of science medical and health sciencesbasic medicinepharmacology and pharmacydrug discoverynatural sciencesphysical sciencesopticsmicroscopymedical and health scienceshealth sciencespersonalized medicinemedical and health sciencesclinical medicinehematology Programme(s) H2020-EU.1.1. - EXCELLENT SCIENCE - European Research Council (ERC) Main Programme Topic(s) ERC-PoC-2016 - ERC-Proof of Concept-2016 Call for proposal ERC-2016-PoC See other projects for this call Funding Scheme ERC-POC - Proof of Concept Grant Host institution CEMM - FORSCHUNGSZENTRUM FUER MOLEKULARE MEDIZIN GMBH Net EU contribution € 146 668,00 Address LAZARETTGASSE 14 AKH BT 25.3 1090 Wien Austria See on map Region Ostösterreich Wien Wien Activity type Private for-profit entities (excluding Higher or Secondary Education Establishments) Links Contact the organisation Opens in new window Website Opens in new window Participation in EU R&I programmes Opens in new window HORIZON collaboration network Opens in new window Total cost € 146 668,00 Beneficiaries (1) Sort alphabetically Sort by Net EU contribution Expand all Collapse all CEMM - FORSCHUNGSZENTRUM FUER MOLEKULARE MEDIZIN GMBH Austria Net EU contribution € 146 668,00 Address LAZARETTGASSE 14 AKH BT 25.3 1090 Wien See on map Region Ostösterreich Wien Wien Activity type Private for-profit entities (excluding Higher or Secondary Education Establishments) Links Contact the organisation Opens in new window Website Opens in new window Participation in EU R&I programmes Opens in new window HORIZON collaboration network Opens in new window Total cost € 146 668,00